Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and Deoxyribonuclease (human clone protein moiety); Dornasa alfa. Date of last search for all years available: 20 May Using the option ‘ Advanced search’, the following search terms were entered into the following fields. El impacto de primer año de tratamiento con dornasa alfa en los parámetros clínicos de pacientes con fibrosis quística: resultado de estudio brasileño.

Author: Kelkis Tojale
Country: Egypt
Language: English (Spanish)
Genre: Automotive
Published (Last): 2 December 2010
Pages: 409
PDF File Size: 4.74 Mb
ePub File Size: 1.91 Mb
ISBN: 384-6-43228-145-6
Downloads: 56321
Price: Free* [*Free Regsitration Required]
Uploader: Malakree

Store it in the refrigerator and protect it from sunlight. Data on patients aged from 6 to 11 years are summarized in Table1.


Due to sample size limitations, no statistical comparisons were made for this group regarding outcomes over time. The formal inclusion of CFQ-R questionnaires as a clinical outcome was essential, as it detected the impact of dornase alfa treatment over QoL, from the perspective of patients and their families.

The significant improvement in the Shwachman-Kulczychi score observed in the older group can also be pointed as a positive outcome of the therapy, and when considered together with the favorable results in CFQ-R other domains 14it allows the conclusion that dornase alfa is an additional therapeutic option for CF.

To review the literature evaluating the efficacy of dornase alfa for non-cystic fibrosis pediatric patients with pulmonary atelectasis. Dornase alfa may be considered as a therapeutic option in non-cystic fibrosis pediatric patients with pulmonary atelectasis, who require treatment intervention when conventional therapy is unsuccessful.

The role of dornase alfa in alfq treatment of cystic fibrosis. University of Aofa Dornase alfa is a biosynthetic form of human deoxyribunuclease I DNase I enzyme. According to the international guidelines, the chronic use of dornase alfa, aiming at dorhasa lung function and reducing exacerbations in children with 6 years of age and older in moderate to severe lung disease, is a strong recommendation, doenasa A, with good level of evidence and substantial benefit 5.

Journal List Rev Paul Pediatr v. Tell your doctor if any of these symptoms are severe or do not go away. Data sources were limited to English language clinical trials and case studies including only children; 8 clinical trials and 12 case reports met the criteria.

Comparison between three or more means was performed using the analysis of variance. Study design, simple size, patient eligibility criteria, and part of patients’ demographic and clinical characteristics have been described previously If you become pregnant while using dornase alfa, call your doctor.


J Pediatr Rio J ; Health-related quality of life HRQoL has gained importance lately as an endpoint for clinical trials, so we have conducted a multicenter prospective study to investigate the impact of dornase alfa introduction on patients’ QoL.

Dornase Alfa

Onset is achieved within 3 to 7 days. Fornasa of airways microbiology is shown in Table 4. It was also recommended for CF patients with mild lung disease by the European Consensus This page was last edited on 17 Februaryat Xlfa breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity. The lack of a comparison group, not treated with dornase alfa, is a limitation that impairs a complete investigation about the benefits of the drug in CF patients.

Caused by a mutation in the cystic fibrosis transmembrane conductance regulator CFTR gene, this disease is characterized by progressive lung destruction, with accumulation of viscous secretions and impairment of mucociliary clearance in airways 34 Chronic pulmonary infection and increased inflammatory response are hallmarks of CF lung disease, with a major impact on patients’ morbidity and the mortality 4 – 6. S aureusP.

Drugs acting on the respiratory system Recombinant proteins. The main method of CF diagnosis was based on two sweat tests associated or not to genetic studies.

Please review our privacy policy. A controlled dotnasa of long-term inhaled hypertonic saline in patients with cystic fibrosis.

You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. Dornase alfa is used to reduce the number of lung infections and to improve lung function in patients with cystic fibrosis.

In all age groups, P. Sputum cultures were collected routinely and considered positive when the following microorganisms were presented in at least one sample: Your doctor may order certain lab tests to check your response to dornase alfa.

Cystic fibrosis at a Brazilian center of excellence: In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections. In a placebo controlled trial investigating the effects of long-term treatment with dornase alfa, it was shown that in young patients with CF, aofa alfa maintains lung function and reduces respiratory tract exacerbations.


Views Read Edit View history. The selection of CF patients in the 16 referral centers was based on the physicians’ decision to initiate chronic treatment with dornase alfa, following the recommendations of current consensus 15with no additional costs to the routine treatment, as this medication is regularly dispensed by our government. It is important to keep all medication out of sight and reach of children as many containers such as weekly pill minders and those for eye drops, creams, patches, and inhalers are not child-resistant and young children can open them easily.

Persistent airway colonization has a devastating impact on patient’s life spam and contributes to local inflammatory response and to progressive deterioration of lung function with age 2 P. alva

Table 1 Outpatient clinic and emergency room doransa, hospitalizations, and pulmonary function parameters in the last 6 months prior to the study entry, and at 6 and 12 months after dornase alfa initiation in patients aged years.

It allowed the identification of baseline reference values dronasa QoL in the different age groups, and the progression of the QoL domains scores over the time 14,15, Do not let anyone else use your medication. Dornase alfa was overall well tolerated, with only a few patients experiencing worsening atelectasis posttreatment.

Keep this medicine in the container it came in, tightly closed, and out of reach of children.

The responsible physician evaluated patient’s medical record forms covering the last six months, prior to study entry T0and at 6 months T2 and 12 months T4 of dornase alfa. Linguistic validation of cystic fibrosis quality alta life questionnaires.

Tabela 5 Uso de tratamentos concomitantes de rotina durante o acompanhamento. Support Center Support Center.

There was a significant reduction in the number of emergency room visits due to acute exacerbations when T4 was compared to T0. Pulmonary dornssa are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Dornase alfa is used as an off-label treatment option for pulmonary atelectasis because limited treatment modalities exist after conventional therapy has failed.